Could Ovascience Inc. (NASDAQ:OVAS) tear in the end?


OvaScience, Inc. (NASDAQ:OVAS) has posted results for the last fiscal year, recording EPS of $-2.21. For this year, EPS is anticipated to grow 5.30% over the preceding year, while next year?s EPS is predicted to increase 20.30%.

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend. The market is approaching overbought territory. Be watchful of a trend reversal.

Shares of OvaScience, Inc. are now trading at $1.90, giving it market cap of $67.20M. Over the last 12 months, shares of OvaScience, Inc. have risen to maximum of $-78.84% and declined to a minimum of $52.00%.

The stock?s beta, which measures volatility, is 3.56. For the purpose of clarity, note that a beta of less than 1 implies that a stock is less volatile versus the overall market, while a beta over 1 indicates a stock is more volatile over the market.

OvaScience, Inc. shows 20-Day Simple Moving Average of $42.48% and 50-Day Simple Moving Average of $36.24%. The 200-Day SMA is $-35.22%.

The stock’s weekly performance is 40.74% while its monthly performance is 42.86%. Year-to-date the equity has moved 24.18% compared to a performance of -63.81% over the preceding 12 months.

OvaScience, Inc. has witnessed 0.00% insider transactions, showing insider ownership of 0.90%. That compares to 65.10% ownership by institutional investors after 7.85% institutional transactions.

Return on investments in OvaScience, Inc. for the last 12 months is -75.10%, while return on assets for the equivalent period is -56.90%. Return on equity for the previous 12 months, on the other hand, is -62.90%.

OvaScience, Inc. has RSI (Relative Strength Index) of 80.95.

OvaScience(SM), Inc. (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Chief Executive Officer Elect, Christopher Kroeger. The award was approved by OvaScience’s Compensation Committee on June 21, 2017 as an inducement material to him entering into employment with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4).

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.